Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private Sector Tatsuya Kondo Becomes PMDA Head

This article was originally published in PharmAsia News

Executive Summary

Japan's International Medical Center President Tatsuya Kondo became the new chief executive of Japan's Pharmaceuticals and Medical Devices Agency, effective April 1. Kondo is the first person to be appointed to the position who was not previously an administrative officer for Ministry of Health, Labor and Welfare. Kondo's immediate predecessor, former MHLW drug division director Akira Miyajima, resigned from the post on Jan. 17. His resignation is believed to be a sign of taking responsibility for ignoring a list of hepatitis C cases caused by contaminated blood products and failing to notify the patients about the information. (Click here for more - Japanese language

You may also be interested in...

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.

COVID-19 Concerns Could Enhance Ongoing Bloom Of Plant-Based Sports Nutrition Sales

"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?" 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts